porporany.	
All rights recorded. No rouse allowed without permission	
All lights reserved. No reuse allowed without permission	ı.
a 1	

1	SYNE1 gene novel variant is associated with myocardial infarction in young people with
2	a family history of premature atherosclerosis.
3	Michał Ambroziak MD, PhD, Assoc. Prof. ^a , Jakub Franke MD ^{b, c} , Anna Wójcicka MD, PhD,
4	Assoc. Prof. ^{b,d} , Monika Kolanowska MD, PhD ^{b,e} , Andrzej Budaj MD, PhD, Prof. ^a
5	
6	^a Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski
7	Hospital; Warsaw, Poland
8	^b Warsaw Genomics; Warsaw, Poland
9	^c II Department of Radiology, Medical University of Warsaw, Warsaw, Poland
10	^d Fundacja Wiedziec Wiecej; Warsaw, Poland
11	^e Department of Tumor Biology and Genetics, Medical University of Warsaw; Warsaw,
12	Poland
13 14	Short title: SYNE1 gene variant in premature atherosclerosis.
15	
16	Corresponding author:
17	Michał Ambroziak; e-mail: madaba@op.pl
18	Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital,
19	04-730 Warsaw, Grenadierów 51/59, phone/fax: +48 22 810-17-38
20	orcid.org/0000-0002-3172-0719
21	

22 Wonst Totsupper review and should not be used to guide clinical practice.

1 Abstract

Aim. The aim of the study was to investigate the role of genetic variants in young patients
(aged <50 years) with myocardial infarction (MI) and a family history of premature
atherosclerosis.

Methods and Results. The studied group consisted of 70 patients aged 26-49 (mean 43.1, SD 5 ± 4.3), 17 women and 53 men, with MI and with a family history of premature atherosclerosis, 6 7 defined as MI or ischaemic stroke in first-degree relatives at age <65 years in women or <55 years in men. The total DNA was extracted from the peripheral blood samples. The targeted 8 9 enrichment library was prepared and analyzed using the Next-Generation Sequencing method. Statistical analyses were performed using the R software package (http://www.r-project.org/). 10 The results of sequencing were compared to data from the reference control population 11 consisting of 597 people with no history of MI (418 women, 179 men) aged 18-83 (mean 12 40.5, SD \pm 12.4) as a whole and after matching with a studied group by age and gender in a 13 proportion 1:3 (210 people, 51 women, 159 men, aged 18-77, mean 42.1, SD ±10.6) using 14 Propensity Score Matching. Risks associated with detected variants were evaluated using 15 Fisher's exact test based on the allelic frequencies of variants in both groups. 16

SYNE1 gene variant rs36215567 (NM_182961.4: c.20396+22A>G) occurs with a significantly higher incidence in the studied group when compared to the control population with OR 4.80 95%CI 1.43-14.45 (p=0.005) as well as when compared to the control population matched by age and gender OR 9.31 95%CI 1.64-95.41 (p=0.004). There were no statistically significant differences in the incidence of variants related to familial hypercholesterolemia such as *LDLR* c.667G>A, *PCSK9* c.658-36G>A, and *APOB* c.12382G>A between both cohorts.

- Conclusion. A novel variant of the *SYNE1* gene is associated with myocardial infarction in
 young patients with a family history of premature atherosclerosis.
- 3
- 4

5 Lay summary

- The wide use of genetic information to predict coronary artery disease (CAD)
 development and incidence, particularly important in young people, still requires
 investigation before clinical implementation.
- A novel variant of the *SYNE1* gene is associated with myocardial infarction (MI) in
 young patients with a family history of premature atherosclerosis.
- Although, the role of SYNE1 in the maintenance of proper function of the cardiac
 muscles and coronary arteries remains still under examination the result of this study
 open a new opportunity to use the *SYNE1* gene variant in genetic risks MI scores.
- 14
- 15

16 Key-words

SYNE1, myocardial infarction at a young age, premature coronary artery disease,cardiovascular disease family history

19

20

1 **1. Introduction**

Cardiovascular diseases (CVDs) are the leading cause of death globally. As the World 2 Health Organization (WHO) reports, an estimated 17.9 million people died from CVDs in 3 4 2019, representing 32% of all global deaths [1]. Ischemic heart disease (IHD) rose from the third to the first leading global cause of premature mortality, measured by years of life lost 5 (YLL), between 1990 and 2019 [2]. In the EUROASPIRE V study, which involved people 6 with confirmed coronary artery disease (CAD), up to 9% of the studied population were 7 patients aged <50 years [3]. According to the Framingham study, the MI incidence for a 10-8 year follow-up differs between the age groups - it was 12.9, 38.2, and 71.2 per 1000 in males 9 and 2.2, 5.2, and 13.0 per 1000 in females in the age groups of 30-34, 35-44, and 45-54 10 11 years, respectively [4].

There are differences in risk factor profiles between individuals who experienced the first myocardial infarction at a very young (\leq 40 years) and a young (age 41-50 years) age. When compared with young patients, very young individuals are more likely to use both marijuana and cocaine [5]. Conversely, patients aged 41 to 50 years are more likely to be diagnosed with hypertension or peripheral vascular disease, use alcohol, and have a higher 10-year atherosclerotic cardiovascular disease risk score. Nevertheless, the overall burden of traditional risk factors was similar between very young and young patients.

The INTERHEART study carried out in 52 countries around the world on more than 12 thousand patients showed that smoking, lipid abnormalities, hypertension, and diabetes as more significant risk factors for MI in younger than in older patients [6]. Apart from those factors, a family history of premature IHD and genetic factors seem to be especially important in young people with MI.

According to the European Society of Cardiology guidelines for CVD prevention, the 1 2 routine use of genetic risk scores is not yet recommended [7]. There is no consensus regarding 3 which genes and corresponding single nucleotide polymorphisms should be included, and whether to use risk factor-specific or outcome-specific polygenic risk scores (PRS) [8]. The 4 addition of a PRS for CAD to pooled cohort equations seems to be associated with a 5 6 statistically significant, yet modest, improvement in the predictive accuracy for incidents of 7 CAD and improved risk stratification for only a small proportion of individuals [9]. Among young adults from the CARDIA study (Coronary Artery Risk Development in Young Adults) 8 9 and Framingham Offspring Study, PRS improved model discrimination for coronary 10 atherosclerosis, but improvements were smaller than those associated with modifiable risk 11 factors [10].

Nevertheless, there is no doubt that genetic information is a valuable complement to 12 traditional factors in CAD risk stratification, particularly in young people. The wide use of 13 genetic information to predict CAD development and incidence still requires investigation 14 15 before clinical implementation. The group of special interest is a population of young people with CAD and a family history of premature IHD, defined as MI or ischemic stroke in first-16 degree relatives at age <55 years in men and <65 years in women [11]. Thus, the aim of our 17 study was to investigate the role of genetic variants in this very special population – young 18 patients with MI and a family history of premature IHD. 19

- 20
- 21 **2.** Subjects and methods
- 22 2.1. Patients

The studied group consisted of 70 patients with MI aged 26-49 (mean 43.1, SD ±4.3;
17 women and 53 men), admitted to the Department of Cardiology, Centre of Postgraduate

Medical Education, Grochowski Hospital in years 2007-2019. All patients had been 1 2 diagnosed MI based on clinical presentation, ecg and biochemical criteria, including MI with ST elevation (STEMI) in 18 cases (25.7%) and MI without ST elevation (NSTEMI) in 52 3 cases (74.3%) and had a family history of premature atherosclerosis, defined as MI or 4 ischemic stroke in first-degree relatives at age <65 years in women or <55 years in men. All 5 patients, except 2 (no consent), had performed coronary angiography revealing 1-vessel 6 7 coronary artery disease (VCAD) in 33 patients (47.1%), 2-VCAD in 17 patients (24.3%), and 8 3-VCAD in 20 patients (28.6%); Table 1. The mean left ventricular ejection fraction (LVEF) was 51.8% (SD ±8.0). 9

There were 15 (21.4%) participants of the study with university degree, 46 (65.7%) with completed high school education and 7 (10%) with completed elementary school education (2 patients have not provided information). Regarding a type of job – there were 37 (52.8%) blue collar workers, 23 (32.9%) white collar workers, 3 (4.3%) unemployed and 2 (2.9%) people on pension (5 patients have not provided information). Regarding marriage status – there were 40 (57.1%) married people in the study, 18 (25.7%) single, 6 (8.6%) divorced, 2 widows and 1 widower (4.3%); 3 patients have not provided information.

All participants of the study provided written informed consent. The Ethical
Committee of the Centre of Postgraduate Medical Education approved the study protocol. The
investigation conforms to the principles outlined in the Declaration of Helsinki.

The results of sequencing were compared to data from the reference Warsaw Genomics control population consisting of 597 people with no history of MI (418 women, new) aged 18-83 (mean 40.5, SD ± 12.4) as a whole and after matching using Propensity Score Matching with a studied group by age and gender in a proportion 1:3 (210 people, 51 women and 159 men, aged 18-77, mean 42.1, SD ±10.6).

1

2 2.2 Anthropometric, clinical and biochemical analysis

3 BMI was calculated as weight (kg)/height (m2). Depression and smoking status, including duration and intensity (cigarette number per day) of smoking, were assessed based 4 on the patient's history. Hypertension was assessed based on the medical history and 5 6 treatment or on a mean value of two measurements of systolic (SBP) and diastolic (DBP) blood pressure performed after at least 5 minutes sitting, made in 5 minute intervals. 7 Hypertension was defined as values ≥140 mmHg SBP and/or ≥90 mmHg DBP according to 8 9 ESH/ESC (European Society of Hypertension, European Society of Cardiology) guidelines. Diabetes mellitus was assessed based on the medical history and treatment or based on fasting 10 plasma glucose ≥ 126 mg/dl or ≥ 200 mg/dl in oral glucose tolerance test according to WHO 11 and ADA (American Diabetes Association) guidelines. 12

Blood samples were collected on admission and the next morning. Biochemical analyses, including glucose, total, HDL, and LDL cholesterol as well as triglycerides (TG) plasma concentrations were performed in fasting blood samples by standard enzymatic methods using COBAS INTEGRA 800 regents and equipment (Roche Diagnostics Gmbh).

17

18 2.3 Genotyping

Total DNA was extracted from whole peripheral blood samples. The extraction was performed on Maxwell® RSC 48 Instrument (Promega) using the Maxwell® RSC Blood DNA Kit, according to the protocol. The targeted enrichment library was prepared and analyzed using the Next-Generation Sequencing (NGS) method. The total DNA input for NGS libraries was 35 ng. The sample libraries were prepared on Biomed i7 (Beckam and

Coulter) with the use of Kapa HyperPlus protocol (Roche Diagnostics). The concentration and 1 2 quality of the libraries were subsequently verified on SpectraMax (Molecular Devices) and TapeStation 4200 and subjected to the hybridization capture (NimbleGen EZ SeqCap, Roche 3 Diagnostics). The hybridization was conducted according to the Roche protocol. The size, 4 concentration, and quality of obtained final NGS library were confirmed by TapeStation 4200 5 and Quantus (Promega). The samples were sequenced on the Hiseq4000 (Illumina), 2x150 6 7 cycles. 8 9 2.4 Statistical analysis Statistical analyses were performed using the R software package (http://www.r-10

project.org/). Risks associated with detected variants were evaluated using Fisher's exact test
 based on the allelic frequencies of variants in both groups.

13

14 **3. Results**

3.1 Anthropometric, biochemical and clinical characteristics of studied and controlgroups.

The mean BMI in the studied group was 28.8 kg/m2 (SD \pm 3.5), total cholesterol level 202.3 mg/dl (SD \pm 3.5), HDL 40.6 mg/dl (SD \pm 9.6), LDL 124.0 mg/dl (SD \pm 28.9), triglycerides 164.4 mg/dl (SD \pm 63.5), glucose 108.3 mg/dl (SD \pm 19.9) and creatinine 0.9 mg/dl (SD \pm 0.2); Table 2. Regarding other risk factors 63 patients (90%) were smokers (mean 24.1 pack-years, SD \pm 13.0), 44 (62.8%) had hypertension, 11 (15.7%) had diabetes mellitus, and 8 (11.4%) had depression; Table 3.

The mean BMI in the control group was 24.5 kg/m2, (SD ± 4.8) with 176 smokers
(29,5%). The mean BMI in the control group matched with a studied group by age and gender
was 26.08 kg/m2 (SD ± 4.3) and this group included 62 smokers (29,5%).

- 4
- 5

3.2 Next-Generation Sequencing

6 The sequencing encompassed the coding sequences of 159 genes with 40 nucleotide 7 intronic flanks. Low quality variants were removed, and the variants of the allele count 8 greater or equal to 5 in the MI group were considered in further analysis. Variants were 9 narrowed down to those classified as at least variants of unknown significance according to the bioinformatic algorithm. This resulted in identification of four variants in LDLR, SYNE1, 10 PCSK9 and APOB genes. Allelic count of these SNPs was assessed in the control group. 11 Furthermore, for each variant Hardy-Weinberg equilibrium was tested in the control 12 population showing (p>0.05). Fisher's exact test was used to check for differences in allelic 13 14 frequencies in both groups; Table 4.

Sequencing and statistical analysis performed in the MI patients and healthy controls revealed the presence of a single variant in the *SYNE1* gene, with an enriched abundance within the patients. We did not observe any statistically significant differences between the frequency of other variants, including known, pathogenic variants related to familial hypercholesterolemia (FH) as well as variants of unknown significance of FH related genes: *LDLR* c.667G>A, *PCSK9* c.658-36G>A, and *APOB* c.12382G>A.

SYNE1 gene variant rs36215567 (NM_182961.4: c.20396+22A>G) is statistically
significantly more prevalent in the studied group in comparison to the control population with
OR 4.80, 95%CI 1.43-14.45 (p=0.005) as well as when compared to the control population
matched by age and gender OR 9.31, 95%CI 1.64-95.41(p=0.004); Figure 1.

Considering that the study group differed significantly in BMI and the number of 1 2 smokers (p<0.001) when compared with both unmatched and matched control population the 3 multivariable logistic regression model was created. The model included smoking status, BMI and presence of SYNE1 rs36215567. The model confirmed this SNP to be an independent risk 4 factor for premature MI with OR 13,86 95% CI 1.64 – 117.45 (p =0.016); Table 5. 5

6

7

4. Discussion

The main aim of this study was to identify single variants predisposing to MI at a 8 9 young age as the genetic background seems to be particularly important in the pathogenesis of CAD in this group. In our previous study we revealed that the younger age of patients with 10 myocardial infarction is associated with a higher number of relatives with a history of 11 premature MI/ischaemic stroke [12]. 12

13 Numerous evidence indicates that CAD at a young age is associated with a genetic 14 background. A significant enrichment of increased polygenic score has been noted among 15 patients with early-onset (age \leq 55 years) MI as compared with population-based controls, with median polygenic score among patients in the 72nd percentile [13]. Both familial 16 17 hypercholesterolemia mutations and high polygenic score were associated with more than three-fold increased odds of early-onset MI. Monogenic familial hypercholesterolemia or a 18 high genome-wide polygenic score confer to a 4- to 5-fold relative risk, which suggests that 19 assessment for familial hypercholesterolemia mutations and genome-wide polygenic scores 20 could be very useful for risk prediction, especially when combined with traditional risk 21 22 factors for CAD [14].

Using data from the UK Biobank on 306,654 individuals without a history of CVD 23 and not receiving lipid-lowering treatments, Sun L et al. calculated risk discrimination and 24

reclassification upon addition of PRSs to risk factors in a conventional risk prediction model 1 2 (i.e., age, sex, systolic blood pressure, smoking status, history of diabetes, and total and highdensity lipoprotein cholesterol) [15]. The addition of information on PRSs increased the C-3 index by 0.012 (95% CI 0.009-0.015) and resulted in continuous net reclassification 4 improvements – among people at intermediate (5% to <10%) 10-year CVD risk could help 5 prevent 1 additional CVD event for approximately every 340 individuals screened. Such a 6 7 targeted strategy could help prevent 7% more CVD events than conventional risk prediction alone. Moreover, it has been shown lastly, that adding PRS to clinical risk assessment has 8 significantly improved identification people who experience a serious CVD event, especially 9 10 in young age - among people aged 40-54 years clinical risk assessment alone identified 11 26.0% (95% CI: 16.5%–37.6%) of those who developed a major CVD event, while the combination of clinical and genetic approach identified 38.4% (95% CI: 27.2%–50.5%) [16]. 12

In this study, we used the Next-Generation Sequencing to identify possible MI-related 13 genetic variants in young patients. Since the familial aggregation of MI is an independent risk 14 15 factor for the disease, we decided to perform an analysis using a panel of 159 genes related to various cardiovascular disorders, including 26 genes that are known to be involved in 16 myopathies and dyslipidemias. Interestingly, our study did not show any statistically 17 important difference in frequencies of variants commonly associated with dyslipidemias 18 between the two studied groups [17]. We identified a single genetic variant in the SYNE1 19 gene, whose prevalence was higher in MI patients. The rs36215567 (NM_182961.4: 20 c.20396+22A>G) variant is located in an intron of a gene, possibly altering splicing of the 21 SYNE1 gene and resulting in altered activity of the translated protein, though the effect of this 22 23 variant on the production of different SYNE1 transcripts has not been described. It is a rare variant occurring at the frequency of 0.89% in the European population (1000 genomes 24 project). 25

SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1; Nesprin1) gene is a 1 2 protein-coding gene located in a long arm of chromosome 6, position 6q25.2. Its protein is a 3 member of the spectrin family of structural proteins that link the nuclear plasma membrane to the actin cytoskeleton. It is expressed in numerous tissues, but it has mainly been mapped to 4 the aortic vascular smooth muscle cells and heart [18]. SYNE1 aberrances were mainly 5 associated with arthrogryposis and muscular dystrophies (Online Mendelian Inheritance in 6 7 Men) but more recent papers identified its involvement in dilated cardiomyopathy [19, 20]. Interestingly, this association results mainly from the presence of alternatively spliced gene 8 isoforms. SYNE1 has been shown also to be involved in the angiotensin-II-induced cardiac 9 10 hypertrophy by miR-525-5p / specific protein transcription factor SP1 axis [21].

Moreover, a recent study revealed an important role of *SYNE1* in cell regeneration and showed that its levels decrease with age possibly leading to a decrease in cardiac function [22]. Thus, even though the exact role of *SYNE1* protein in cardiovascular homeostasis is still largely unknown, a growing number of data suggest its role in the maintenance of proper function of the cardiac and arterial muscles.

There are also available data indicating a possible role of *SYNE1* variants (although others than shown in our study) in the development of CAD by the involvement in the morbidity of hypercholesterolemia and hypertriglyceridemia through gene-gene and SNP-SNP interactions [23]. It suggests, considering the results of our study, other potential genegene interactions including *SYNE1* gene variants in the pathogenesis of CAD.

The main limitation of this study is the relatively small number of participants. The assumptions of the study, including young patients with MI and a family history of premature atherosclerosis, make this population very unique, but at the same time difficult to enlarge. On the other hand, the high homogeneity of the groups, limited to the Polish Caucasian

population, may be important in the context of potential population and racial differences in 1 2 the pathogenesis of CAD, especially when analyzing genetic risk factors. Moreover, this the first report regarding potential role of SYNE1 in premature CAD which means that there are 3 no similar data in wide databases yet as well as functional studies carried out to elucidate 4 potential mechanisms. However, this strengthens the value of our finding. 5 6 In conclusion: a novel variant of the SYNE1 gene is associated with myocardial 7 infarction in young age patients with a family history of premature atherosclerosis. Nevertheless, the wide use of such genetic information to predict CAD development and 8 incidences still requires further investigation including wide genetic and functional studies 9 10 before clinical implementation. 11 12 13 **Source of Funding** 14 This work was supported by Grant No. 501-1-10-14-20 from the Centre of Postgraduate 15 16 Medical Education, Warsaw, Poland. 17 Disclosures 18 All authors declare no conflict of interest. 19 20 21 22 13

1 References

2	1.	https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
3	2.	Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme
4		AK, Buxton AE, Carson AP, Commodore-Mensah Y et al. Heart Disease and Stroke
5		Statistics—2022 Update: A Report From the American Heart Association. Circulation
6		2022;145:e153–e639.
7	3.	Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, Maggioni A,
8		Marques-Vidal P, Jennings C, Abreu A et al. Lifestyle and impact on cardiovascular
9		risk factor control in coronary patients across 27 countries: Results from the European
10		Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol
11		2019;26:824-835.
12	4.	Kannel WB Abbott RD. Incidence and prognosis of unrecognized myocardial
13		infarction. An update on the Framingham study. NEJM 1984;311:1144-7.
14	5.	Yang J, Biery DW, Singh A, Divakaran S, DeFilippis EM, Wu WY, Klein J, Hainer J,
15		Ramsis M, Natarajan P et al. Risk Factors and Outcomes of Very Young Adults Who
16		Experience Myocardial Infarction: The Partners YOUNG-MI Registry. Am J Med.
17		2020;133:605–612.
18	6.	Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A,
19		Pais P, Varigos J et al. INTERHEART Study Investigators. Effect of potentially
20		modifiable risk factors associated with myocardial infarction in 52 countries (the
21		INTERHEART study): case-control study. Lancet, 2004;364:937-952.
22	7.	Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A,
23		Biffi A, Boavida JM, Capodanno D et al. ESC National Cardiac Societies; ESC

1	Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease
2	prevention in clinical practice: Developed by the Task Force for cardiovascular
3	disease prevention in clinical practice with representatives of the European Society of
4	Cardiology and 12 medical societies with the special contribution of the European
5	Association of Preventive Cardiology (EAPC). European Heart Journal
6	2021;42:3227–3337.
7	8. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores.
8	Hum Mol Genet. 2019;28:R133–R142.
9	9. Elliott J, Bodinier B, Bond TA, Chadeau-Hyam M, Evangelou E, Moons KGM,
10	Dehghan A, Muller DC, Elliott P, Tzoulaki I. Predictive Accuracy of a Polygenic Risk
11	Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery
12	Disease. JAMA 2020;323: 636-645.
13	10. Welss QS, Bagheri M, Aday AW, Gupta DK, Shaffer ChM, Wei W-Q, Vaitinadin NS,
14	Khan SS, Greenland Ph, Wang TJ et al. Polygenic Risk Score to Identify Subclinical
15	Coronary Heart Disease Risk in Young Adults. Circ Genom Precis Med
16	2021;14:e003341.
17	11. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, Levy D, Murabito JM, Wang TJ,
18	Wilson PWF, O'Donnell ChJ. Parental cardiovascular disease as a risk factor for
19	cardiovascular disease in middle-aged adults: a prospective study of parents and
20	offspring. JAMA 2004;291:18.
21	12. Ambroziak M, Niewczas-Wieprzowska K, Maicka A, Budaj A. Younger age of
22	patients with myocardial infarction is associated with a higher number of relatives
23	with a history of premature atherosclerosis. BMC Cardiovasc Disord 2020 11;20:410.

1	13. Khera AV, Chaffin M, Zekavat SM, Collins RL, Roselli C, Natarajan P, Lichtman JH,
2	D'Onofrio G, Mattera J, Dreyer R et al. Whole genome sequencing to characterize
3	monogenic and polygenic contributions in patients hospitalized with early-onset
4	myocardial infarction. Circulation 2019;139:1593–1602.
5	14. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P,
6	Lander ES, Lubitz SA, Ellinor PT et al. Genome-wide polygenic scores for common
7	diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet
8	2018;50(9): 1219–1224.
9	15. Sun L, Pennells L, Kaptoge S, Nelson ChP, Ritchie SC, Abraham G, Arnold M, Bell
10	S, Bolton T, Burgess S et al. Polygenic risk scores in cardiovascular risk prediction: A
11	cohort study and modeling analyses. PLoS Med 2021;18:e1003498.
12	16. Samani NJ, Beeston E, Greengrass Ch, Riveros-McKay F, Debiec R, Lawday D,
13	Wang Q, Budgeon ChA, Braund PS, Bramley R et al. Polygenic risk score adds to a
14	clinical risk score in the prediction of cardiovascular disease in a clinical setting.
15	European Heart Journal 2024;00:1–9.
16	17. Ranthe MF, Petersen JA, Bundgaard H, Wohlfahrt J, Melbye M, Boud HA. A Detailed
17	Family History of Myocardial Infarction and Risk of Myocardial Infarction - A
18	Nationwide Cohort Study. PLOS ONE 2015;10:e0125896.
19	18. Zhang Q, Skepper JN, Yang F, Davies JD, Hegyi L, Roberts RG, Weissberg PL, Ellis
20	JA, Shanahanl CM. Nesprins: a novel family of spectrin-repeat-containing proteins
21	that localize to the nuclear membrane in multiple tissues. J. Cell Sci 2001;114:4485-
22	4498.

23 19. OMIM, <u>www.omim.org</u>, entry # 608441

1	20. Zhou C, Li C, Zhou B, Sun H, Koullourou V, Holt I, Puckelwartz MJ, Warren DT,
2	Hayward R, Lin Z et al. Novel nesprin-1 mutations associated with dilated
3	cardiomyopathy cause nuclear envelope disruption and defects in myogenesis. Hum
4	Mol Genet 2017;26:2258-2276.
5	21. Wang Y, Cao R, Yang W, Qi B. SP1-SYNE1-AS1-miR-525-5p feedback loop
6	regulates Ang-II-induced cardiac hypertrophy. J Cell Physiol 2019;234:14319-14329.
7	22. Dong J, Liu J, Wen Y, Tobin SW, Zhang C, Zheng H, Huang Z, Feng Y, Zhang D, Liu
8	S. Down-Regulation of Lnc-CYP7A1-1 Rejuvenates Aged Human Mesenchymal
9	Stem Cells to Improve Their Efficacy for Heart Repair Through SYNE1. Front Cell
10	Dev Biol 2020;8:600304.
11	23. Zheng PF, Yin RX, Liu ChX, Deng GX, Guan YZ, Wei BL. SYNE1-QK1 SNPs, G \times
12	G and G \times E interactions on the risk of hyperlipidaemia. J Cell Mol Med
13	2020;24:5772-5785.
14	
15	
16	
17	
18	
19	
20	
21	
22	17

1 Figures

- 3 Figure 1
- 4 SYNE1 gene variant rs36215567 (NM_182961.4: c.20396+22A>G) LDLR c.667G>A,
- *PCSK9* c.658-36G>A, and *APOB* c.12382G>A incidence in the studied group (70 patients)
- 6 compared to the control population matched by age and gender (210 people); Fisher's exact
- 7 test.
- *APOB* apolipoprotein B gene, CI confidence intervals, G guanine, *LDLR* low density
 lipoprotein receptor gene, OR odds ratio, *PCSK9* proprotein convertase subtilisin/kexin
 type 9 gene, SNP single nucleotide polymorphism, *SYNE1* spectrin repeat containing
 nuclear envelope protein 1 gene.

1 Tables

- 2
- 3 Table 1
- 4 Clinical and haemodynamic characteristics of studied group (70 patiens).
- 5 CAD coronary artery disease, LVEF left ventricle ejection fraction, NSTEMI non-ST
- 6 elevation myocardial infarction, SD standard deviation, STEMI ST elevation myocardial
- 7 infarction.

8

- 9 Table 2
- 10 Anthropometric and biochemical characteristics of studied group (70 patients).
- 11 BMI body mass index, HDL high density lipoprotein, LDL low density lipoprotein, SD
- 12 standard deviation.
- 13
- 14 Table 3
- 15 CAD risk factors in studied group (70 patients).
- 16 CAD coronary artery disease.
- 17
- 18 Table 4

Analyzed SNPs characteristic – number of genotypes (wild type/alternative
heterozygote/alternative homozygote) in studied group (70 patients) and in control group
unmatched (597 people) and matched by age and sex (210 people).

A – adenine, APOB – apolipoprotein B gene, G – guanine, LDLR – low density lipoprotein
 receptor gene, MI – myocardial infarction, PCSK9 – proprotein convertase subtilisin/kexin
 type 9 gene, SNP – single nucleotide polymorphism, SYNE1 - spectrin repeat containing
 nuclear envelope protein 1 gene.

5

6 Table 5

Multivariable regression model included smoking status, BMI and presence of SYNE1
rs36215567 variant confirmed this SNP as an independent risk factor for premature MI;
studied group - 70 patients, control group - 597 people; Fisher's exact test, *statistically
significant.

BMI – body mass index, CI – confidence intervals, MI – myocardial infarction, OR – odds
 ratio, SNP – single nucleotide polymorphism, SYNE1 - spectrin repeat containing nuclear
 envelope protein 1 gene.



2

1

3 Figure 1

SYNE1 gene variant rs36215567 (NM_182961.4: c.20396+22A>G) LDLR c.667G>A, *PCSK9* c.658-36G>A, and *APOB* c.12382G>A incidence in the studied group (70 patients)
compared to the control population matched by age and gender (210 people); Fisher's exact
test.

APOB – apolipoprotein B gene, CI – confidence intervals, G – guanine, *LDLR* – low density
lipoprotein receptor gene, OR – odds ratio, *PCSK9* – proprotein convertase subtilisin/kexin
type 9 gene, SNP – single nucleotide polymorphism, *SYNE1* - spectrin repeat containing
nuclear envelope protein 1 gene.

Table 1.

Clinical and haemodynamic characteristics of studied group (70 patiens).

CAD – coronary artery disease, LVEF – left ventricle ejection fraction, NSTEMI – non-ST elevation myocardial infarction, SD – standard deviation, STEMI – ST elevation myocardial infarction.

Clinical and haemodynamic	Number of affected patients	
characteristics	n (%)	
	mean (±SD)	
STEMI	18 (25.7%)	
nSTEMI	52 (74.3%)	
1-vessel CAD	33 (47.1%)	
2-vessel CAD	17 (24.3%)	
3-vessel CAD	20 (28.6%)	
LVEF mean	51.8% (SD ±8.0)	

Table 2.

Anthropometric and biochemical characteristics of studied group (70 patients).

BMI - body mass index, HDL - high density lipoprotein, LDL - low density lipoprotein, SD

- standard deviation.

Studied group characteristics	mean (±SD)
BMI kg/m2	28.8 (±3.5)
Total cholesterol mg/dl	202.3 (±3.5)
HDL mg/dl	40.6 (±9.6)
LDL mg/dl	124.0 (±28.9)
Triglycerides mg/dl	164.4 (±63.5)
Glucose mg/dl	108.3 (±19.9)
Creatinine mg/dl	0.9 (±0.2)

Table 3.

CAD risk factors in studied group (70 patients).

CAD – coronary artery disease.

Number of affected patients		
n (%)		
63 (90%)		
44 (62.8%)		
11 (15.7%)		
8 (11.4%)		
-		

Table 4:

Analyzed SNPs characteristic – number of genotypes (wild type/alternative heterozygote/alternative homozygote) in studied group (70 patients) and in control group unmatched (597 people) and matched by age and sex (210 people).

A – adenine, APOB – apolipoprotein B gene, G – guanine, LDLR – low density lipoprotein receptor gene, MI – myocardial infarction, PCSK9 – proprotein convertase subtilisin/kexin type 9 gene, SNP – single nucleotide polymorphism, SYNE1 - spectrin repeat containing nuclear envelope protein 1 gene.

Gene	SNP	MI group	Control group	Control group
	(genotypes)		(unmatched)	(matched)
SYNE1	rs36215567	64/6/0	586/11/0	208/2/0
	(AA/AG/GG)			
LDLR	rs11669576	61/7/0	541/48/1	198/10/0
	(GG/GA/AA)			
PCSK9	rs11800265	61/5/0	414/43/1	150/14/0
	(GG/GA/AA)			
APOB	rs1801703	65/5/0	587/9/0	207/3/0
	(GG/GA/AA)			

Table 5:

Multivariable regression model included smoking status, BMI and presence of *SYNE1* rs36215567 variant confirmed this SNP as an independent risk factor for premature MI; studied group – 70 patients, control group – 597 people; Fisher's exact test, *statistically significant.

BMI – body mass index, CI – confidence intervals, MI – myocardial infarction, OR – odds ratio, SNP – single nucleotide polymorphism, SYNE1 - spectrin repeat containing nuclear envelope protein 1 gene.

Variable	OR	OR (95% CI)	P value
BMI	1.13	1.05 – 1.23	0.001*
Smoking status	19.40	8.19 - 45.94	<0.001*
<i>SYNE1</i> rs36215567 variant	13.86	1.64 – 117.45	0.016*